SCHEMBL3767484

SCHEMBL3767484

COc1ccc(-c2ccc(N3CCN(CC(=O)N4CCN(C5CCC5)CC4)CC3)nn2)cc1OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 3/20 0.49
POLB P06746 2/20 0.49
ALDH1A1 P00352 2/20 0.49
HPGD P15428 1/20 0.49
HRH3 Q9Y5N1 1/20 0.47
HSD17B10 Q99714 2/20 0.46
TSHR P16473 1/20 0.46
MAPT P10636 2/20 0.46
TP53 P04637 3/20 0.45
PKM P14618 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
ALOX15 P16050 1/20 0.45
THRB P10828 1/20 0.45
RAB9A P51151 3/20 0.42
NPC1 O15118 1/20 0.42
CFTR P13569 1/20 0.42
ATM Q13315 1/20 0.41
KMT2A Q03164 1/20 0.41
AURKA O14965 1/20 0.41
TLR9 Q9NR96 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3779376 0.93 HRH3 (0.46) MAPK1POLBALDH1A1HPGDHRH3
SCHEMBL3774746 0.92 LMNA (0.46) MAPK1POLBALDH1A1HPGDHRH3
SCHEMBL3803432 0.91 ALDH1A1 (0.48) MAPK1POLBALDH1A1HPGDHRH3
SCHEMBL3770163 0.88 HRH3 (0.49) MAPK1ALDH1A1HPGDHRH3HSD17B10
SCHEMBL3767881 0.88 HRH3 (0.47) MAPK1ALDH1A1HRH3TSHRMAPT
SCHEMBL3771986 0.88 ACHE (0.49) MAPK1ALDH1A1HPGDHRH3HSD17B10
SCHEMBL3767549 0.87 MAPK1 (0.50) MAPK1POLBALDH1A1HRH3HSD17B10
SCHEMBL3771050 0.87 HSD17B10 (0.46) MAPK1POLBALDH1A1HPGDHRH3
SCHEMBL3763255 0.86 HRH3 (0.43) HRH3MAPTTP53NPSR1THRB
SCHEMBL3762981 0.86 RAB9A (0.47) ALDH1A1HPGDHRH3HSD17B10TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 MAPK1 3915/4885POLB 4363/4885ALDH1A1 1210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.